Evidence map›Paper›PMID 27476656›Full record

ArticleAmerican journal of human genetics2016

Truncating Mutations in the Adhesion G Protein-Coupled Receptor G2 Gene ADGRG2 Cause an X-Linked Congenital Bilateral Absence of Vas Deferens.

Olivier Patat, Adrien Pagin, Aurore Siegfried, Valérie Mitchell, Nicolas Chassaing, Stanislas Faguer, Laetitia Monteil, Véronique Gaston, Louis Bujan, Monique Courtade-Saïdi and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in American journal of human genetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed, 1 pooled it
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 1 synthesis or guideline pooled it, 160 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Adhesion G protein-coupled receptors.Pharmacological reviews · 2026
    Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Olivier PatatService de Génétique Médicale, Hôpital Purpan, Centre Hospitalier Universitaire, 31059 Toulouse, France.
Adrien PaginService de Toxicologie et Génopathies, Centre de Biologie Pathologie Génétique, Centre Hospitalier Régional Universitaire, 59037 Lille, France.
Aurore SiegfriedDépartement d'Anatomie et Cytologie Pathologiques, Institut Universitaire du Cancer Toulouse- Oncopole, Centre Hospitalier Universitaire, 31059 Toulouse, France.
Valérie MitchellSpermiologie et CECOS, Institut de Biologie de la Reproduction, Hôpital Jeanne de Flandre, Centre Hospitalier Régional Universitaire, 59000 Lille, France; EA4308 Gamétogenèse et Qualité du Gamète, Université Lille II, 59000 Lille, France.
Nicolas ChassaingService de Génétique Médicale, Hôpital Purpan, Centre Hospitalier Universitaire, 31059 Toulouse, France.
Stanislas FaguerDépartement de Néphrologie et Transplantation d'Organes, Hôpital Rangueil, Centre Hospitalier Universitaire, 31059 Toulouse, France.
Laetitia MonteilService de Génétique Médicale, Hôpital Purpan, Centre Hospitalier Universitaire, 31059 Toulouse, France.
Véronique GastonService de Génétique Médicale, Hôpital Purpan, Centre Hospitalier Universitaire, 31059 Toulouse, France.
Louis BujanGroupe Activité Médecine de la Reproduction, CECOS, Centre Hospitalier Universitaire, 31059 Toulouse, France; EA3694 Groupe de Recherche en Fertilité Humaine, Université Toulouse III, 31059 Toulouse, France.
Monique Courtade-SaïdiDépartement d'Anatomie et Cytologie Pathologiques, Institut Universitaire du Cancer Toulouse- Oncopole, Centre Hospitalier Universitaire, 31059 Toulouse, France.
François MarcelliEA4308 Gamétogenèse et Qualité du Gamète, Université Lille II, 59000 Lille, France; Département d'Andrologie, Hôpital Calmette, Centre Hospitalier Régional Universitaire, 59000 Lille, France.
Guy LalauService de Toxicologie et Génopathies, Centre de Biologie Pathologie Génétique, Centre Hospitalier Régional Universitaire, 59037 Lille, France.
Jean-Marc RigotEA4308 Gamétogenèse et Qualité du Gamète, Université Lille II, 59000 Lille, France; Département d'Andrologie, Hôpital Calmette, Centre Hospitalier Régional Universitaire, 59000 Lille, France.
Roger MieussetEA3694 Groupe de Recherche en Fertilité Humaine, Université Toulouse III, 31059 Toulouse, France; Groupe Activité Médecine de la Reproduction, Département d'Andrologie, Hôpital Paule de Viguier, Centre Hospitalier Universitaire, 31059 Toulouse, France.
Eric BiethService de Génétique Médicale, Hôpital Purpan, Centre Hospitalier Universitaire, 31059 Toulouse, France. Electronic address: bieth.e@chu-toulouse.fr.
Centre Hospitalier Universitaire de Toulouse · FRCentre Hospitalier Universitaire de Lille · FRUniversité Toulouse III - Paul Sabatier · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In 80% of infertile men with obstructive azoospermia caused by a congenital bilateral absence of the vas deferens (CBAVD), mutations are identified in the cystic fibrosis transmembrane conductance regulator gene (CFTR). For the remaining 20%, the origin of the CBAVD is unknown. A large cohort of azoospermic men with CBAVD was retrospectively reassessed with more stringent selection criteria based on consistent clinical data, complete description of semen and reproductive excurrent ducts, extensive CFTR testing, and kidney ultrasound examination. To maximize the phenotypic prioritization, men with CBAVD and with unilateral renal agenesis were considered ineligible for the present study. We performed whole-exome sequencing on 12 CFTR-negative men with CBAVD and targeted sequencing on 14 additional individuals. We identified three protein-truncating hemizygous mutations, c.1545dupT (p.Glu516Ter), c.2845delT (p.Cys949AlafsTer81), and c.2002_2006delinsAGA (p.Leu668ArgfsTer21), in ADGRG2, encoding the epididymal- and efferent-ducts-specific adhesion G protein-coupled receptor G2, in four subjects, including two related individuals with X-linked transmission of their infertility. Previous studies have demonstrated that Adgrg2-knockout male mice develop obstructive infertility. Our study confirms the crucial role of ADGRG2 in human male fertility and brings new insight into congenital obstructive azoospermia pathogenesis. In men with CBAVD who are CFTR-negative, ADGRG2 testing could allow for appropriate genetic counseling with regard to the X-linked transmission of the molecular defect.

Indexed as

Gene DeletionCystic Fibrosis Transmembrane Conductance RegulatorDNA Mutational AnalysisExomeFemaleGenes, X-LinkedHumansMaleMale Urogenital DiseasesPedigreeReceptors, G-Protein-CoupledVas DeferensADGRG2 protein, humanCystic Fibrosis Transmembrane Conductance RegulatorReceptors, G-Protein-Coupled

Identifiers

PMID27476656
PMCPMC4974083
OpenAlexW2489827014

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.